Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands
NCT01536626 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 211
Last updated 2017-02-24
Summary
This study is conducted in Europe. The aim of this observational study is to observe and investigate the process of switching from premixed human insulin 30/70 (BHI 30) to biphasic insulin aspart 30/70 (BIAsp 30) in an outpatient setting.
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Interventions
- DRUG
-
biphasic insulin aspart 30
Prescription at the discretion of the treating physician
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-06-09
- Primary Completion
- 2007-04-10
- Completion
- 2007-04-10
Countries
- Netherlands
Study Locations
More Related Trials
-
Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment
NCT01548235 ·Status: COMPLETED
-
Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30
NCT00675493 ·Status: COMPLETED
-
Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes
NCT00715663 ·Status: COMPLETED
-
Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose Control
NCT00700960 ·Status: COMPLETED
-
An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment
NCT00696995 ·Status: COMPLETED
-
Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes
NCT00704223 ·Status: COMPLETED
-
Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs
NCT01486862 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes
NCT00600366 ·Status: COMPLETED ·Phase: PHASE4
-
Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes
NCT01565733 ·Status: COMPLETED
-
Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers
NCT01707160 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes
NCT01520818 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes
NCT01704378 ·Status: COMPLETED ·Phase: PHASE4
-
Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes
NCT01536639 ·Status: COMPLETED
-
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes
NCT01467323 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin
NCT00670722 ·Status: COMPLETED
-
Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice
NCT01492166 ·Status: COMPLETED
-
Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes
NCT01467401 ·Status: COMPLETED ·Phase: PHASE4
-
Post Marketing Surveillance Study of Biphasic Insulin Aspart 30
NCT01536613 ·Status: COMPLETED
-
Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects
NCT01527643 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes
NCT01526941 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes
NCT01536028 ·Status: COMPLETED ·Phase: PHASE1
-
Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes
NCT00696163 ·Status: COMPLETED
-
Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes
NCT01526980 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes
NCT00729898 ·Status: COMPLETED
-
Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
NCT00671008 ·Status: COMPLETED